Dupont De Nemours

DD · NYSE

$132.96+$3.62 (+2.80%)TodayMarket closed · Oct 20, 7:31 PM ET

Prev close $129.34

DD analyst rating

BuyConsensus of 13 analysts over the last 12 months. 77% rate it a buy.

Strong buy0
Buy10
Hold3
Underperform0
Sell0

12-month price target · 20 analysts

Average $170.92 (+28.6% upside)

Low: $154.53
Now: $132.96
High: $195.30

Upgrades and downgrades

The latest rating actions, newest first

DD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Oct 15, 2026	Maintains	Outperform	$176.00 → $160.00	46%
Barclays	Oct 13, 2026	Initiates	Overweight	$156.00	50%
JP Morgan	Oct 9, 2026	Downgrade	Overweight → Neutral	$172.00 → $145.00	64%
Citigroup	Oct 7, 2026	Maintains	Buy	$170.00 → $162.00	53%
UBS	Oct 5, 2026	Maintains	Buy	$178.00 → $172.00	49%
JP Morgan	Aug 10, 2026	Maintains	Overweight	$171.00 → $172.00	64%
RBC Capital	Aug 7, 2026	Maintains	Outperform	$180.00 → $176.00	46%
UBS	Aug 5, 2026	Maintains	Buy	$175.00 → $178.00	49%
Citigroup	Jul 2, 2026	Maintains	Buy	$168.00 → $170.00	53%
Morgan Stanley	Jun 23, 2026	Maintains	Equal-Weight	$52.00 → $156.00	61%

The case for and against

Updated Oct 18, 2026

Bull case

DuPont de Nemours is well positioned by its shift toward higher-quality, higher-multiple businesses, with Healthcare and Water Technologies delivering mid-single-digit organic sales growth and expected to remain the main profit engines. The company is generating solid free cash flow, with >100% cash conversion in Q2, a further $250M share-repurchase program in 2026, and roughly $1B available for bolt-on opportunities, supporting both shareholder returns and growth investment. Its balance sheet has improved materially after about $5B of debt repayment, while continued organic improvement, healthy margins near 24.5%, and exposure to aerospace, biopharma, and semiconductor end markets underpin a constructive outlook into 2027.

Bear case

DuPont de Nemours is viewed cautiously because its recovery depends on a slower-than-expected rebound in China and North America, while continued weakness in electronics and construction could keep demand pressured. Its negative outlook is also tied to synergy and integration challenges, along with the risk that management delays or fails to optimize the spin strategy and the electronics business separation. In the downside scenario, 2026E EBITDA of $2.17 and a 21x multiple imply only $46 of value, underscoring how execution setbacks and weak end markets could weigh on fundamentals.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.